Thermo Fisher Scientific (TMO) Stock Could Be 18% Overvalued Despite Cell Therapy Growth News
Thermo Fisher Scientific (TMO) Stock Could Be 18% Overvalued Despite Cell Therapy Growth News Simply Wall St
Covered in this story
Analyst targets on Thermo Fisher Scientific
- Morgan Stanley: $663 → $730 by Oct 2027 · Overweight via ad-hoc-news.de
- UBS: $606 → $730 by Sep 2027 · Buy via Investing.com
- Morgan Stanley: $560 → $650 by Jul 2027 · Overweight via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $TMO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Thermo Fisher Scientific →Dalsna Finance is currently tracking 42 stories mentioning Thermo Fisher Scientific, the earliest published 23 Apr 2026.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.